ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin

被引：108
|
作者：
Tomlinson, B. [1 ]
Hu, M. [1 ]
Lee, V. W. Y. [2 ]
Lui, S. S. H. [1 ]
Chu, T. T. W. [1 ]
Poon, E. W. M. [1 ]
Ko, G. T. C. [1 ,3 ]
Baum, L. [2 ]
Tam, L. S. [1 ]
Li, E. K. [1 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Sch Pharm, Shatin, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Hong Kong Inst Diabet & Obes, Shatin, Hong Kong, Peoples R China
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷 / 05期
关键词：
COA REDUCTASE INHIBITORS; PHARMACOKINETICS; BCRP; PHARMACOGENETICS; ATORVASTATIN; TRANSPORTER; EXPRESSION; VARIANTS; GENOTYPE; OATP1B1;
D O I：
10.1038/clpt.2009.232
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The ATP-binding cassette G2 (ABCG2) c.421C>A (rs2231142) polymorphism influences the pharmacokinetics of rosuvastatin. We examined whether this polymorphism influences the low-density lipoprotein cholesterol (LDL-C)lowering efficacy of the drug. In 305 Chinese patients with hypercholesterolemia who were treated with rosuvastatin at a dosage of 10 mg daily, the c.421A variant was found to be significantly associated with greater reduction in LDL-C level, in a gene-dose-dependent manner. As compared with subjects with the c.421CC genotype, those with the c.421AA genotype showed a 6.9% greater reduction in LDL-C level, which would be equivalent to the effect obtained by doubling the dose of rosuvastatin.
引用
收藏
页码：558 / 562
页数：5
相关论文
共 50 条
  • [21] Relation of Low-Density Lipoprotein Cholesterol Level to Plaque Rupture
    Kurihara, Osamu
    Kim, Hyung Oh
    Russo, Michele
    Araki, Makoto
    Nakajima, Akihiro
    Lee, Hang
    Takano, Masamichi
    Mizuno, Kyoichi
    Jang, Ik-Kyung
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 134 : 48 - 54
  • [22] Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein Cholesterol Levels With Rosuvastatin 40 mg Daily (from the ASTEROID Study)
    Wiviott, Stephen D.
    Mohanavelu, Satishkumar
    Raichlen, Joel S.
    Cain, Valerie A.
    Nissen, Steven E.
    Libby, Peter
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (01) : 29 - 35
  • [23] Low-density lipoprotein cholesterol lowering therapies: what is on the horizon?
    Gadi, Ramprasad
    Figueredo, Vincent M.
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2015, 16 (01) : 1 - 10
  • [24] Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
    Akutsu, Noriyuki
    Sasaki, Shigeru
    Matsui, Takeshi
    Akashi, Hirofumi
    Yonezawa, Kazuhiko
    Ishigami, Keisuke
    Tsujisaki, Masayuki
    Isshiki, Hiroyuki
    Yawata, Atsushi
    Yamaoka, Satoshi
    Ban, Toshihiro
    Adachi, Takeya
    Nakahara, Seiya
    Takagi, Hideyasu
    Nakachi, Kohei
    Tanaka, Katsunori
    Hirano, Takehiro
    Yamamoto, Itaru
    Kaneto, Hiroyuki
    Wagatsuma, Kohei
    Numata, Yasunao
    Nakase, Hiroshi
    INTERNAL MEDICINE, 2021, 60 (21) : 3369 - 3376
  • [25] Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients
    Liu, Chin-San
    Lii, Chong-Kuei
    Chang, Li-Ling
    Kuo, Chen-Ling
    Cheng, Wen-Ling
    Su, Shih-Li
    Tsai, Chia-Wen
    Chen, Haw-Wen
    NUTRITION RESEARCH, 2010, 30 (02) : 118 - 124
  • [26] Higher low-density lipoprotein cholesterol levels are associated with decreased mortality in patients with intracerebral hemorrhage
    Chang, Jason J.
    Katsanos, Aristeidis H.
    Khorchid, Yasser
    Dillard, Kira
    Kerro, Ali
    Burgess, Lucia Goodwin
    Goyal, Nitin
    Alexandrov, Anne W.
    Alexandrov, Andrei V.
    Tsivgoulis, Georgios
    ATHEROSCLEROSIS, 2018, 269 : 14 - 20
  • [27] Oxidized low-density lipoprotein (LDL) and LDL cholesterol are associated with outcomes of minor stroke and TIA
    Wang, Anxin
    Dai, Liye
    Zhang, Nan
    Lin, Jinxi
    Chen, Guojuan
    Zuo, Yingting
    Li, Hao
    Wang, Yilong
    Meng, Xia
    Wang, Yongjun
    ATHEROSCLEROSIS, 2020, 297 : 74 - 80
  • [28] A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering
    Leusink, Maarten
    Maitland-van der Zee, Anke H.
    Ding, Bo
    Drenos, Fotios
    van Iperen, Erik P. A.
    Warren, Helen R.
    Caulfield, Mark J.
    Cupples, L. Adrienne
    Cushman, Mary
    Hingorani, Aroon D.
    Hoogeveen, Ron C.
    Hovingh, G. Kees
    Kumari, Meena
    Lange, Leslie A.
    Munroe, Patricia B.
    Nyberg, Fredrik
    Schreiner, Pamela J.
    Sivapalaratnam, Suthesh
    de Bakker, Paul I. W.
    de Boer, Anthonius
    Keating, Brendan J.
    Asselbergs, Folkert W.
    Onland-Moret, N. Charlotte
    PHARMACOGENOMICS, 2016, 17 (06) : 583 - 591
  • [29] Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response
    Voora, Deepak
    Shah, Svati H.
    Reed, Carol R.
    Zhai, Jun
    Crosslin, David R.
    Messer, Chad
    Salisbury, Benjamin A.
    Ginsburg, Geoffrey S.
    CIRCULATION-CARDIOVASCULAR GENETICS, 2008, 1 (02) : 100 - 106
  • [30] Association between the ABCG2 C421A polymorphism and Alzheimer's disease
    Feher, Agnes
    Juhasz, Anna
    Laszlo, Anna
    Pakaski, Magdolna
    Kalman, Janos
    Janka, Zoltan
    NEUROSCIENCE LETTERS, 2013, 550 : 51 - 54
12345